A 61-year-old man is evaluated in the hospital for 3 days of fever, dry cough, pleuritic c… — USMLE Step 3

A 61-year-old man is evaluated in the hospital for 3 days of fever, dry cough, pleuritic chest pain, and mild hemoptysis. His medical history is significant for an orthotopic heart transplant 3 years ago for nonischemic cardiomyopathy and a history of recurrent unprovoked deep venous thrombosis. His current medications include tacrolimus, mycophenolate mofetil, prednisone, and warfarin.

Vital signs are temperature $38.6^\circ\text{C}$ ( $101.5^\circ\text{F}$ ), pulse $102/\text{min}$ , blood pressure $118/74\text{ mmHg}$ , and respirations $20/\text{min}$ . Pulse oximetry shows $94\%$ on room air.

Laboratory results:

Test	Result
Leukocyte count	$3,200/\mu\text{L}$
Serum creatinine	$1.4\text{ mg/dL}$
INR	$2.4$

A serum galactomannan assay is markedly elevated. A non-contrast CT of the chest reveals a $3\text{ cm}$ macronodule in the right upper lobe surrounded by a halo of ground-glass attenuation.

The infectious disease service diagnoses invasive pulmonary aspergillosis and recommends initiating intravenous voriconazole.

Which of the following simultaneous pharmacologic interventions are indicated for this patient? (Select all that apply)

Decrease the daily dose of tacrolimusAnswer
Decrease the weekly dose of warfarinAnswer
C
Substitute voriconazole with high-dose fluconazole
D
Initiate concurrent rifampin therapy
E
Discontinue prednisone therapy

Answer

The indicated interventions are to decrease the daily dose of tacrolimus and decrease the weekly dose of warfarin.

Voriconazole is the standard of care for invasive pulmonary aspergillosis. However, it is a triazole antifungal that potently inhibits multiple cytochrome P450 enzymes, most notably CYP3A4 and CYP2C9. In a heart transplant recipient maintained on tacrolimus (a calcineurin inhibitor metabolized by CYP3A4), the introduction of voriconazole drastically increases tacrolimus serum concentrations, which can cause acute nephrotoxicity and neurologic side effects. Standard protocols dictate reducing the tacrolimus dose by 50% to 75% when starting voriconazole. Furthermore, this patient is taking warfarin for recurrent deep venous thrombosis. The more potent S-enantiomer of warfarin is metabolized by CYP2C9. Inhibition of CYP2C9 by voriconazole will rapidly elevate the patient's INR, exposing him to a high risk of life-threatening bleeding. Preemptive reduction of the warfarin dose (typically by 30% to 50%) along with frequent INR monitoring is mandatory.

Step-by-Step Solution

Identify the primary diagnosis and indicated treatment.

The patient has invasive pulmonary aspergillosis (fever, hemoptysis, halo sign on CT, positive galactomannan) requiring voriconazole therapy.

Establishing the correct antimicrobial is necessary before anticipating drug-drug interactions.

Analyze the pharmacokinetic profile of the newly initiated medication.

Voriconazole is a potent inhibitor of cytochrome P450 enzymes, particularly CYP3A4, CYP2C9, and CYP2C19.

Understanding the enzyme inhibition profile is critical for managing polypharmacy safely.

Reconcile the patient's current medication list against the new pharmacokinetic profile.

Tacrolimus relies on CYP3A4 for clearance. Warfarin relies heavily on CYP2C9 for clearance of its active enantiomer.

Identifying which specific maintenance drugs will be affected by enzyme inhibition prevents iatrogenic harm.

Determine the necessary clinical interventions.

Preemptively decrease the doses of both tacrolimus and warfarin to avoid tacrolimus toxicity (nephrotoxicity, profound immunosuppression) and warfarin toxicity (hemorrhage).

Failure to adjust these medications prior to or at the exact time of voriconazole initiation predictably leads to severe adverse events.

Key Concept

Initiation of voriconazole requires preemptive dose reductions of medications metabolized by CYP3A4 (e.g., tacrolimus) and CYP2C9 (e.g., warfarin) to prevent severe drug toxicity.

Question

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Topics

More questions from this topic